Phase I/II Study of RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Everolimus (Primary) ; Gemcitabine (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2017 Status changed from active, no longer recruiting to completed.
- 10 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.